News from orexo A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 17, 2019, 09:14 ET Orexo's Closest Upcoming Presentations at Conferences

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the company will...


May 02, 2019, 02:25 ET Orexo: Interim Report Q1 2019

Q1 2019 highlights Total net revenues of SEK 174.3 million (139.7), up 24.8 percent Zubsolv® US net revenues of SEK 161.7 million (131.1), up 23.3...


Apr 26, 2019, 11:42 ET Issues of Shares Following the Vesting of 2016/2019 Incentive Plan

The 2016 annual general meeting of Orexo resolved on a long-term incentive plan for senior executives and key employees within the Orexo group ("LTIP ...


Apr 11, 2019, 12:54 ET Report from Orexo AB's Annual General Meeting

Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 11 April 2019 resolved, in accordance with the...


Mar 29, 2019, 11:27 ET District Court of Delaware Rules that Actavis does not Infringe with their Suboxone® and Subutex® Generics

Orexo AB (publ.), the fully integrated specialty pharmaceutical company, with strong long-term patent protection (no. 8,940,330) for its key product, ...


Mar 21, 2019, 05:42 ET Orexo Publishes the Annual Report for 2018

Orexo's Annual Report, including the Sustainability Report, for the 2018 fiscal year has been published and can be downloaded on the company's...


Mar 05, 2019, 12:14 ET Notice of Annual General Meeting of Orexo

The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on...


Feb 28, 2019, 12:11 ET Number of Shares and Votes in Orexo

The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company's incentive programs....


Jan 30, 2019, 02:24 ET Q4 Incl. Full Year Report 2018

Q4 2018 highlights Total net revenues of SEK 227.1 million (191.0), up 18.9 percent from Q4 previous year Zubsolv® US net revenue of SEK 166.7...


Jan 11, 2019, 02:13 ET Actavis Infringes Orexo's Long Term Zubsolv® U.S. Patent ´330

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the United States...


Jan 07, 2019, 02:15 ET Positive Results From Human PK Study Assessing Orexo's New Intranasal Naloxone Formulations for Opioid Overdose Reversal

Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces positive results from...


Dec 13, 2018, 01:08 ET Orexo Regains Rights to Zubsolv® in all Countries Outside the US

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the Company will...


Dec 06, 2018, 01:44 ET Orexo Hosts Capital Markets Day Today in Stockholm, Sweden

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, is today hosting the Company's Capital...


Nov 30, 2018, 02:16 ET US Court of Appeals Denies Actavis's Petition for Rehearing Regarding Validity of the Zubsolv® Patent

Orexo AB (publ.) today announces that the US Court of Appeals for the Federal Circuit has denied Actavis Elizabeth LLC's (Actavis) combined petition...


Nov 28, 2018, 08:26 ET Agenda - Orexo Capital Markets Day, Stockholm, Sweden, Dec. 6

Orexo AB (publ.), the specialty pharmaceutical company, invites as earlier communicated investors, analysts and media to its Capital Markets Day in...


Nov 08, 2018, 07:43 ET Orexo to Host a Capital Markets Day on Dec. 6 With the US President´s Former Advisor as Keynote Speaker

rexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, invites investors, analysts and media to ...


Oct 25, 2018, 02:10 ET Orexo - Interim Report Q3 2018

The win in the patent litigation strengthen Orexo's long term business opportunities Q3 2018 highlights Orexo wins appeal against Actavis on Zubsolv...


Oct 24, 2018, 07:52 ET Save the Date: Orexo to Host Capital Markets Day on Dec. 6 With the US President´s Former Advisor as Key Note Speaker

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the Company will...


Oct 24, 2018, 02:49 ET Orexo Appoints Joseph DeFeo as New CFO

Orexo AB announces today that the company appoints Joseph DeFeo as the company's new Chief Financial Officer (CFO) from November 1, 2018. Joseph...


Oct 08, 2018, 11:58 ET Orexo Appoints Nomination Committee and Publishes Financial Calendar 2018/2019

Prior to the Annual General Meeting 2019, Orexo appoints a Nomination Committee which represents approximately 45 percent of the number of shares and ...


Oct 01, 2018, 02:20 ET Orexo Internalizes Contract Field Force in the US to Further Strengthen the Commercial Organization

Orexo AB (publ) today announces that the field representatives in the contracted field force have been offered direct employment with Orexo US Inc....


Sep 10, 2018, 15:14 ET Orexo Wins Appeal Against Actavis on Zubsolv Patent in the US

Orexo AB (publ.) today announces that the US Court of Appeals for the Federal Circuit found Orexo's long term Zubsolv patent US 8,940,330 to be...


Jul 11, 2018, 02:43 ET Orexo: Interim Report Q2 2018

Q2 2018 highlights Total net revenues of SEK 199.7 million (159.1), up 25.5 percent from Q2 previous year Zubsolv US net revenue of SEK 158.4 million ...


Jun 29, 2018, 12:08 ET Number of Shares and Votes in Orexo

The number of shares and votes in Orexo AB has changed as a result of the issue and repurchase of 325,000 class C shares as announced on June 15,...


May 31, 2018, 02:56 ET Orexo´s CFO Resigns and Will Leave the Company in November 2018

Orexo AB today announces that Henrik Juuel has notified the company of his resignation after working for five years as the company´s Chief Financial...